Researchers analyzing data from the National Institutes of Health’s All of Us Research Program have found that a patient’s step count following surgery is a powerful, objective predictor… read more.
Although the United States requires a warning label on alcoholic beverages, alcohol-related deaths have risen steadily over the past two decades. However, new labels warning of specific disease… read more.
NICE(UK): Vorasidenib can be used as an option to treat grade 2 astrocytoma or oligodendroglioma in people 12 years and over when: i) the cancer has a susceptible… read more.
Insomnia is a common problem, affecting as many as 20% to 60% of perimenopausal and postmenopausal US women. Because of its possible severe physical and psychological effects, ongoing… read more.
Only 43% of menu items at the UK’s highest-grossing restaurant chains met all their voluntary targets for sugar, salt, and calorie reduction, as set by the UK Government…. read more.
The EMA’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Mekinist. The marketing… read more.
Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to… read more.
Groundbreaking research from the University of Houston shows that a single low-dose atropine eye drop can produce daylong effects in managing myopia, or nearsightedness, which affects roughly one-third of U.S…. read more.
On 23 April 2026, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending a change to the terms of the marketing authorisation for… read more.
Whether a dog owner rewards their dog with a treat or corrects it by pulling on the leash is not simply a matter of what they believe to… read more.
It is quite possible that in the near future, people will have to describe their symptoms to an AI before they can get a doctor’s appointment. The AI… read more.
Johnson & Johnson announced that the FDA has approved a supplemental New Drug Application (sNDA) based on long-term data evaluating the safety and efficacy of Caplyta (lumateperone) for… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
